The chemistry — DPA in the omega-3 family
The long-chain omega-3 fatty acid family contains three principal members: EPA (eicosapentaenoic acid, 20:5 n-3), DPA (docosapentaenoic acid, 22:5 n-3), and DHA (docosahexaenoic acid, 22:6 n-3). The numbering convention indicates carbon length and double-bond count: EPA has 20 carbons and 5 double bonds; DPA has 22 carbons and 5 double bonds; DHA has 22 carbons and 6 double bonds. The omega-3 (n-3) designation indicates the position of the first double bond from the methyl-end — three carbons from the end in all three.
Per Holub 2009 review, DPA is the metabolic intermediate between EPA and DHA in the elongation-desaturation conversion pathway: dietary EPA is elongated to DPA via elongase enzymes, and DPA is then desaturated to DHA via the delta-6 desaturase. The pathway runs in reverse partially as well — tissues can convert DPA back to EPA via beta-oxidation under certain metabolic conditions. The interconvertibility means dietary DPA effectively raises both EPA and DHA tissue pools, even when not directly consumed. See our omega-3 fatty acids explainer for the broader long-chain omega-3 framework.
Where DPA appears in fish oils and other sources
Per Bauer 2011 (JAVMA) marine oil reference data and Park 2010 (Mar Drugs) review, DPA is present in essentially all fish oils, but at lower percentages than EPA and DHA. Salmon oil typically contains 2–4% DPA. Sardine oil contains approximately 1–2% DPA. Anchovy oil contains 1–3% DPA. Krill oil contains 0.5–1.5% DPA. Seal oil is the notable outlier at approximately 4–6% DPA — the highest natural source on a percentage basis — but seal oil is not used in U.S. pet food.
The pet-food consequence: when a dog food contains a fish oil at typical inclusion (0.5–2.5% dry matter omega-3), DPA exposure follows automatically at approximately 0.01–0.10% of dry matter. A 25 kg dog eating 300 g/day of a kibble at 1.5% omega-3 dry matter and 3% DPA-of-omega-3 ingests approximately 14 mg DPA/day. The amounts are small compared with the AAHA 2022 EPA + DHA therapeutic doses (combined 100–310 mg/kg/day — approximately 2,500–7,750 mg/day for a 25 kg dog), but the DPA contribution is automatic and does not require separate formulation decisions.
The evidence base — what DPA does that EPA and DHA don’t
Per Kanayasu-Toyoda 1996 (Lipids) cell-culture and animal-model study, DPA shows anti-platelet aggregation activity at concentrations comparable to EPA. Per Phang 2009 (PUFA metabolism review), DPA tissue incorporation is distinct from EPA: DPA preferentially accumulates in arterial smooth muscle and platelet membranes. Per Holub 2009 review, the human epidemiology associates higher dietary DPA with cardiovascular endpoints in some cohort analyses, though the mechanism may operate through DPA’s conversion to EPA and DHA rather than direct DPA activity.
The canine clinical relevance is currently limited. Per AAHA 2022 Pain Management Guidelines and Roush 2010 (JAVMA) four-paper canine osteoarthritis dosing series, the EPA + DHA evidence base in canine osteoarthritis is Tier 1 (strong); DPA is not separately characterized as a therapeutic target. Per ACVIM 2022 nutritional cardiomyopathy consensus, the canine cardiac evidence base focuses on combined EPA + DHA, taurine, L-carnitine, and CoQ10 — DPA is not a current targeted intervention. Future canine clinical trials may differentiate DPA, but for current pet-food formulation, DPA exposure is bundled with fish-oil inclusion.
Why pet food labels rarely declare DPA
Per AAFCO 2024 Pet Food Labeling Rule, omega-3 fatty acid disclosure follows two patterns. The first pattern is a single guaranteed analysis line for “omega-3 fatty acids” as a percentage of the food. The second pattern is separate guaranteed analysis lines for EPA and DHA when the food is marketed for joint, skin, or cardiac support. AAFCO 2024 does not require a DPA line and labels rarely include one. The reasons are practical: (a) DPA percentages in fish oils are low (1–5%), so a DPA disclosure does not meaningfully change the omega-3 marketing math; (b) the canine clinical evidence base for marketing claims is built on EPA + DHA, so formulators have no marketing incentive to feature DPA; (c) supplier certificates of analysis (COAs) do not always report DPA as a standard line item, making DPA disclosure operationally cumbersome.
The disclosure practice may shift if canine clinical research separates DPA from the EPA + DHA bundle in osteoarthritis, cardiac, or cognitive contexts. For now, dog owners reading labels should treat DPA as an automatic consequence of fish-oil inclusion rather than as a target of separate dietary intervention. See our salmon oil explainer, sardine oil explainer, and krill oil explainer for the marine-omega-3 supply pathways that deliver DPA alongside EPA and DHA.
How KibbleIQ scores DPA-containing formulations
The KibbleIQ Dry Kibble Rubric does not score DPA as an independent ingredient. DPA is captured within the rubric’s broader marine omega-3 evaluation: foods that declare a fish oil at meaningful inclusion (top 10 ingredients with declared omega-3 fatty acid percentage on the guaranteed analysis) earn the rubric’s joint-support and skin-support credit per AAHA 2022 evidence rating — with DPA exposure assumed to follow the EPA + DHA delivery from the labeled fish oil source.
The rubric does not penalize foods that omit DPA from labels. The rubric does not award credit for foods that highlight DPA in marketing without parallel EPA + DHA disclosures — per AAHA 2022 evidence rating, the EPA + DHA combination remains the canine-relevant therapeutic anchor. For dogs with osteoarthritis, cardiac concerns, or skin-and-coat needs, the actionable rubric guidance is to look for declared EPA + DHA percentages or named fish oils in the top 10 ingredients — DPA delivery follows. See best dog food for joint problems, best dog food for heart disease, and best dog food for skin and coat. To check your dog’s food, paste the ingredient list into the KibbleIQ analyzer.